Zai Lab Limited (ZLAB)

NasdaqGM: ZLAB · Real-Time Price · USD

25.64

-0.37 (-1.42%)

At close: Aug 25, 2026, 8:00 PM

25.31

-3.29%

Pre-market: 7:00 AM

The price, the headline numbers and the latest news, in one place.

-1.42% (1D)

No data available

Bid	13.12
Market Cap	2.94B
Revenue (ttm)	449.61M
Net Income (ttm)	-188.21M
	0.78
	-1.7
	n/a
	-12.7
P/B (ttm)	4.39
P/S (ttm)	6.53
Earnings Date	Nov 5, 2026

Ask	23.88
Volume	1,151,362
Avg. Volume (20D)	1,017,104
Open	25.48
Previous Close	26.01
Day's Range	25.25 - 25.96
52-Week Range	15.96 - 35.45
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ZLAB

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammat...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 20, 2017

Employees 1,784

Stock Exchange NasdaqGM

Ticker Symbol ZLAB

Website https://www.zailaboratory.com

Full Company Profile

Financial Performance

In 2025, Zai Lab's revenue was 460.16M, an increase of 15.33% compared to the previous year's 398.99M. Earnings were -175.54M, a decrease of -31.73%.

Financial Statements

Earnings Surprise

Zai Lab has released their quarterly earnings on Aug 6, 2026:

Revenue of $106.31M misses estimates by $0, with -3.33% YoY decline.
EPS of -0.46 exceeds estimates by 0.18, with -24.32% YoY decline.

Next Earnings Release

Zai Lab Limited is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

News

5 days ago · Insider Monkey

Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)?

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adul...